All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

MRKMerck Sharp & Dohme LLC
5Calm
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Running, no new patientsPhase 3990 patientsMain results: Nov 20, 2026
HCMHutchmed
0Calm
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Signing up patientsPhase 1/2186 patientsMain results: Dec 31, 2028
SMMTSummit Therapeutics
0Calm
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Signing up patientsPhase 3780 patientsMain results: Apr 2028
NVSNovartis Pharmaceuticals
5Calm
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Not started yetPhase 251 patientsMain results: Mar 23, 2032
SLGLSol-Gel Technologies, Ltd.
0Calm
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
FinishedPhase 3113 patientsMain results: Aug 20, 2026
NVSNovartis Pharmaceuticals
5Calm
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Running, no new patientsPhase 319 patientsMain results: Feb 26, 2027
BMYBristol-Myers Squibb
10Calm
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Signing up patientsPhase 2182 patientsMain results: Dec 29, 2028
MRKMerck Sharp & Dohme LLC
5Calm
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Running, no new patientsPhase 3868 patientsMain results: Jun 25, 2030
BMYBristol-Myers Squibb
10Calm
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Running, no new patientsPhase 31,230 patientsMain results: Mar 15, 2029
HCMHutchmed
0Calm
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Signing up patientsPhase 2/3502 patientsMain results: May 31, 2028
JNJJanssen Research & Development, LLC
5Calm
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
FinishedPhase 2316 patientsMain results: Dec 4, 2023
AMGNAmgen
2Calm
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Signing up patientsPhase 3400 patientsMain results: Sep 24, 2027
ARVNArvinas Inc.
1Calm
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Running, no new patientsPhase 1/276 patientsMain results: Nov 30, 2026
GNPXGenprex, Inc.
0Calm
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Signing up patientsPhase 1/2158 patientsMain results: Mar 2028
ERASErasca, Inc.
0Calm
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
FinishedPhase 1/285 patientsMain results: Jul 1, 2026
MAIAMaia Biotechnology
0Calm
THIO Sequenced With Cemiplimab in Advanced NSCLC
Running, no new patientsPhase 2227 patientsMain results: Sep 30, 2027
DWTXDogwood Therapeutics Inc.
0Calm
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Running, no new patientsPhase 2240 patientsMain results: Dec 2026
REGNRegeneron Pharmaceuticals
5Calm
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Running, no new patientsPhase 1/295 patientsMain results: Jul 6, 2027
GILDGilead Sciences
1Calm
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
Not started yetPhase 280 patientsMain results: May 2029
GSKGlaxoSmithKline
0Calm
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Signing up patientsPhase 1/247 patientsMain results: Sep 28, 2028
REGNRegeneron Pharmaceuticals
5Calm
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Signing up patientsPhase 3369 patientsMain results: May 3, 2030
ONCBeOne Medicines
2Calm
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Signing up patientsPhase 1/2630 patientsMain results: Mar 31, 2027
COGTCogent Biosciences, Inc.
10Calm
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Signing up patientsPhase 2140 patientsMain results: Sep 19, 2025
IOVAIovance Biotherapeutics, Inc.
0Calm
A Study of IOV-5001 in Adults With Advanced Solid Tumors
Not started yetPhase 1/2106 patientsMain results: Mar 2034
NVSNovartis Pharmaceuticals
15Calm
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
FinishedPhase 262 patientsMain results: May 17, 2024